While the radiopharmaceutical market is attracting a lot of attention and capital, one company will plant its flag in the production of radioisotopes for curative use.
NorthStar Medical Radioisotopes, a Wisconsin-based radioisotope manufacturer, will develop its CDMO business with a new production facility to manufacture radiopharmaceuticals used to treat cancer patients.
The company’s new CDMO wing will aim to provide participating companies with a wider diversity of progress and publicity, as well as advance their internal radiopharmaceutical programs.
The new facility is next to its existing production facility in the city of Beloit, WI. The new 36,000-square-foot facility will be operational until the end of 2024 and will produce some of its isotopes, adding actinium-225 and copper-67.
According to an email from a Northstar spokesperson to Endpoints News, the company has about 300 workers and plans to rent more as a result of the expansion. However, the company did not disclose the value of the facility.
The NorthStar spokesperson also said that several corporations have expressed interest in NorthStar’s CDMO facility for patient dose production, with other corporations interested in NorthStar’s functions to facilitate curative drug progression efforts. In August, NorthStar was one of 3 brands that signed a contract with Aktis Oncology to manufacture actinium-225, which biotechnology uses in experimental cancer therapies with radioligands.
Stephen Merrick, CEO of NorthStar Medical, in a statement:
NorthStar’s CDMO will allow us to share our expertise in developing and commercializing radiopharmaceuticals with pharmaceutical or biotechnology corporations that may require more infrastructure, resources or expertise needed to develop complex radiopharmaceuticals to help them expand and deliver products that have the foresight to address even more than one of the world’s needs. patients with serious illnesses.
The production plant plans to have committed suites for the composition and filling of prescription drugs, as well as quality and quality control departments, analytical departments and logistics spaces for packaging and processing. ‘office.
NorthStar moves to CDMO as the radiopharmaceutical market heats up as big names in the pharmaceutical industry and small biotech companies expand radiopharmaceutical assets.
Over the summer, Berlin-based Ariceum Therapeutics, which was formed by taking the biopharmaceutical candidate along with a team of Ipsen researchers, secured a 25 million euro ($26. 7 million) Series A.
For Novartis, the FDA this year introduced its active radioligand, known as Lu-PSMA-617 and now announced as Pluvicto, for metastatic PSMA-positive and castration-resistant prostate cancer. Novartis acquired the drug when it bought Endocyte for $2. 1 billion in 2018. .
And earlier this spring, Sequoia China filed a $37 million Series A into Shanghai-based Full-Life Technologies to expand a portfolio of radioactive cancer therapies.
In today’s global economic environment, there is a growing need to work smarter, faster and more successfully in all aspects of the life sciences industry. Increasingly limited investments to boost their science. It is vital to recognize that, in this context, many of those small corporations already lack the resources to design and manage clinical trials themselves, as they do not have giant groups or in-house experts to navigate aspects of drug development. This can be a challenge for more complex and difficult-to-treat diseases where there is no previous pathway and patients expect urgent breakthroughs.
After releasing better-than-expected information Wednesday morning about two midterm studies, Prometheus Biosciences’ chief executive said the company would “take some time to evaluate” its upcoming investment options.
It took about seven hours. On Wednesday afternoon, after the market closed, the biotech said it would seek $250 million through an inventory offering as the company looks to outperform anti-TL1A competitor Pfizer and its new partner Roivant.
Unlock this story right away and sign up to have over 154,100 biopharmaceutical professionals read Endpoints daily, and it’s free.
When you run a special report for a fourth year, it might start to feel a bit like a ritual. It goes through the movements, in our case, it opens up nominations for the most productive women in R.
But then things happen that remind you why you’re doing it in the first place. Perhaps a Supreme Court will make a decision to overturn the constitutional right to abortion and an organization of leading women in biotechnology will make it clear that they strongly disagree; perhaps new insights into gender diversity in the industry are emerging that look too much like the old ones, suggesting that women are still dramatically underrepresented at the top; Perhaps the protests and conflicts around the world put in stark terms the struggles that many women still face to obtain maximum fundamental recognition.
Unlock this story right away and sign up to have over 154,100 biopharmaceutical professionals read Endpoints daily, and it’s free.
Kristen Hege leads Bristol Myers Squibb’s Early Discovery in Oncology program, which continues the same work at Celgene, which she acquired through BMS in 2019. tumors. more than 25 years ago.
However, the eminent doctor-researcher is more than the brain of a drug manufacturer. She’s also a practicing physician, mother of two young women, a passionate backpacker, and crosses all of those interests: an advocate for young women and other people of color in STEM and life sciences.
Unlock this article and others by subscribing to one of our paid plans.
More and more women are at the forefront of innovation and in leadership positions in biotechnology, as evidenced by the publication of the list of the 20 most sensible women in the world of R
Currently, in the U. S. pharmaceutical industry, about 46 of all roles are held by women, according to the U. S. Bureau of Labor Statistics. According to a Bloomberg report, women’s roles in the industry have increased dramatically after the pandemic began.
The halo effect of Covid-19 on the pharmaceutical industry continues, according to a new global study from Ipsos. The annual survey of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) shows great goodwill on the part of consumers in relation to confidence-building. measures, cooperation with governments and the advancement of studies and drug development.
“While the pandemic in many countries is no longer the main fear in general, it is again the main fear as a physical fitness factor, the reputation of the industry has returned to being positive,” said Thomas Fife-Schaw, director of studies at Ipsos.
Unlock this story right away and sign up to have over 154,100 biopharmaceutical professionals read Endpoints daily, and it’s free.
Singapore has long established itself as a major hub for pharmaceutical manufacturing, and now several major players will further consolidate their presence in Lion City.
Takeda, Sanofi and GSK are partnering with the Singapore-based Agency for Science, Technology and Research (A*STAR) and several local educational institutions, adding the National University of Singapore, Nanyang Technological University, Singapore, its trading company called NTUitive and the Singapore Institute of Technology to further encourage biologics manufacturing.
The San Antonio Breast Cancer Symposium is taking hold this week, and so far, some of the Big Pharma is generating new testing insights into some of the largest in the space.
First, Novartis announced that its drug, Kisqali, has demonstrated approximately one year of progression-free survival in patients with other first-line metastatic breast cancers. The drug CDK 4/6 was first approved by the FDA in 2017, putting it in direct competition with Pfizer’s Ibrance.
Gossamer Bio$GOSS on Tuesday morning published a statistically significant improvement at its number one endpoint in the key phase II TORREY trial for the lead drug seralutinib. – which will be the number one endpoint of Phase III – because knowledge of either criterion did not meet expectations, lacking an analyst’s bar even for modest success.
Unlock this article and others by subscribing to one of our paid plans.
© Endpoints Company 2022
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.